SCHEMBL4331899

SCHEMBL4331899

NC(=S)N(Cc1ccccn1)N=Cc1ccc(-c2cc(F)cc(F)c2)o1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.37
MAPT P10636 4/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
KDM4E B2RXH2 3/20 0.37
TDP1 Q9NUW8 2/20 0.37
NSD2 O96028 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HPGD P15428 5/20 0.35
ALDH1A1 P00352 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ALOX12 P18054 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
PKM P14618 1/20 0.35
GRM5 P41594 1/20 0.35
SLC9A1 P19634 1/20 0.33
GFER P55789 1/20 0.33
HTT P42858 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4322273 0.92 MAPT (0.38) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL4464604 0.86 TP53 (0.38) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL4329325 0.86 SLC9A1 (0.36) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL4324316 0.85 MAPT (0.38) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL4451555 0.84 KDM4E (0.50) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL4338702 0.81 NPFFR1 (0.50) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL4330988 0.81 NPFFR1 (0.53) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL4338712 0.79 MAPT (0.51) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL4331903 0.74 HKDC1 (0.57) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL4331896 0.74 HKDC1 (0.57) LMNAMAPTMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 LMNA 4884/4885MAPT 3619/4885MEN1 4874/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 LMNA 4885/4885MAPT 3876/4885MEN1 4872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.